GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » Additional Paid-In Capital

Estrella Immunopharma (Estrella Immunopharma) Additional Paid-In Capital : $24.13 Mil(As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Additional Paid-In Capital?


Estrella Immunopharma's quarterly additional paid-in capital stayed the same from Sep. 2023 ($24.13 Mil) to Dec. 2023 ($24.13 Mil) and stayed the same from Dec. 2023 ($24.13 Mil) to Mar. 2024 ($24.13 Mil).

Estrella Immunopharma Additional Paid-In Capital Historical Data

The historical data trend for Estrella Immunopharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Additional Paid-In Capital Chart

Estrella Immunopharma Annual Data
Trend Jun21
Additional Paid-In Capital
-

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 - 24.13 24.13 24.13

Estrella Immunopharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Estrella Immunopharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Estrella Immunopharma (Estrella Immunopharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » Additional Paid-In Capital
Comparable Companies
EYEN FGEN ADCT VANI IPA AFMD KNTE KZR SABS ELTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608
Website
https://www.estrellabio.com
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines